NCT01561924View on ClinicalTrials.gov

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
Interventions
DRUG

eptacog alfa (activated)

Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.

Trial Locations (7)

8200

Novo Nordisk Investigational Site, Århus N

19104

Novo Nordisk Investigational Site, Philadelphia

52242

Novo Nordisk Investigational Site, Iowa City

69003

Novo Nordisk Investigational Site, Lyon

90027

Novo Nordisk Investigational Site, Los Angeles

94704

Novo Nordisk Investigational Site, Berkeley

E1 2AD

Novo Nordisk Investigational Site, London

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY